ArticlePloS one2026
Breakthrough infections and incomplete vaccine efficacy drive pathogen immune escape.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWhile vaccines effectively reduce disease severity and mortality, their consequences for pathogen immune escape remain poorly understood. Vaccines provide protection through three distinct mechanisms: prevention of infection, reduction of symptoms, and limitation of transmission. When vaccine efficacy is incomplete across multiple dimensions, breakthrough infections in vaccinated individuals may paradoxically increase pathogen escape pressure. This study investigates how vaccine efficacy profiles and coverage levels jointly affect escape pressure. MATERIALS AND
methodsWe developed a deterministic compartmental transmission model incorporating three distinct vaccine efficacy parameters: prevention of infection, reduction of symptoms, and limitation of transmission. The model quantifies differential contributions of symptomatic and asymptomatic infections in vaccinated and unvaccinated populations to immune escape pressure.
resultsInfection-blocking, symptom-blocking, and transmission-blocking immunity each reduced escape pressure, although no single component alone was sufficient to suppress escape pressure across most conditions. Combinations of efficacy components produced greater reductions. When vaccine efficacy was low across multiple components, increasing coverage could paradoxically elevate escape pressure above pre-vaccination levels. Even in a fully vaccinated population, escape pressure could exceed the pre-vaccination level when infection-blocking and symptom-blocking efficacy were simultaneously low. The effectiveness of symptom-blocking immunity depended on infection-blocking efficacy - when infection-blocking efficacy is low, symptom-blocking efficacy alone did not always suppress escape pressure below pre-vaccination levels. DISCUSSION: The effect of vaccination on immune escape depends on both vaccine efficacy profiles and coverage levels. Increasing vaccination coverage may increase rather than reduce escape pressure when efficacy is low across multiple dimensions. Combining efficacy across multiple dimensions produced greater reductions in escape pressure than relying on a single efficacy component.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.